Featured News
GI Partners Acquires CDMO and Cell Solutions
Introducing Rose BioSolutions: Engineered to Deliver
In May 2026, GI Partners acquired the established CDMO and Cell Solutions businesses from Charles River and formed Rose BioSolutions, supporting the biotechnology ecosystem with cell sourcing capabilities and CDMO services designed to accelerate your early-stage research and advanced therapy from development to delivery.
As an independent company, Rose Bio is engineered to deliver end-to-end advanced therapy solutions for clients, providing full-service contract development and manufacturing (CDMO) capabilities across plasmid DNA, viral vector, and cell therapy, as well as integrated cell sourcing products and services.
In a press release announcing the news, Ahmad Hussin, Global Head of CDMO and Chief Operating Officer at Rose Bio (formerly Charles River), commented: "Demand for advanced therapies continues to grow, underscoring the importance of having a trusted partner at all stages of the research, development, and manufacturing processes and making our solutions and expertise more important than ever before. By bringing together one of the industry's broadest portfolios of cellular starting materials with world-class manufacturing capabilities across cell therapies, viral vectors, and plasmid DNA, we are well positioned to deliver comprehensive solutions with the reliability, quality, and scale our customers need to move programs forward and bring therapies to patients."